Nuvectra is a neurostimulation medical device company focused on the development and commercialization of its neurostimulation technology platform for the treatment of various disorders through stimulation of tissues associated with the nervous system. Co.'s neurostimulation technology platform has the potential to provide treatment to patients in several neurostimulation markets, including spinal cord stimulation (SCS), sacral neuromodulation, deep brain stimulation, and other emerging neurostimulation markets. Co.'s Algovita® SCS system (Algovita), is an application of its neurostimulation technology platform and is indicated for the treatment of chronic pain of the trunk and/or limbs. The NVTR average annual return since 2016 is shown above.
The Average Annual Return on the NVTR average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NVTR average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NVTR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|